Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2024-02-15 Director's Dealing
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
Board Role Change and Launch of EIP
Director's Dealing Classification · 1% confidence The document is an RNS announcement (indicated by 'RNS Number : 1927D') dated February 15, 2024. The primary content announces two key events: 1) A change in Board role (Non-Executive Chairman becoming Executive Chairman) and 2) The launch of an Employee Performance Incentive Plan (EIP) involving the grant of options to senior management. The latter part of the document transitions into a mandatory disclosure format detailing transactions by Persons Discharging Managerial Responsibilities (PDMRs) regarding the grant of these options, which is typical for insider dealing/director dealing disclosures required under market abuse regulations. While it mentions remuneration/incentives, the core focus is on management changes and insider transactions. The most specific category covering personal share transactions by directors/executives is 'Director's Dealing' (DIRS). Although it also covers management changes (MANG), the detailed transaction tables strongly point towards DIRS being the primary classification for the regulatory filing aspect.
2024-02-15 English
Market Opportunity for POLB 001 for CRS
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7309C' and concludes with information about RNS, the news service of the London Stock Exchange, stating that RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content itself is an announcement regarding positive independent research confirming a large market opportunity for a drug candidate (POLB 001) and strategic focus on rare diseases. This structure—a brief announcement disseminated via the RNS system—indicates a general regulatory news service release. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a proxy statement (DEF 14A), and it is a general market-moving announcement distributed through the official regulatory channel, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2024-02-12 English
Further data shows POLB001 potential in cancer CRS
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '17 January 2024'. It contains key highlights about clinical data ('POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)'), market opportunity, and an announcement about an upcoming investor presentation. The structure, use of RNS identifiers, and the nature of the content (a press release announcing positive clinical trial data and business updates) strongly indicate a regulatory news service announcement. Since it is a general announcement of material information that doesn't fit the specific categories like Earnings Release (ER) or a formal report (10-K, IR), the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback.
2024-01-17 English
RSV AI Drug Candidate Analysis Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '20 December 2023'. It announces 'Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI' by Poolbeg Pharma PLC. The closing section explicitly states: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which is best classified under the 'Regulatory Filings' (RNS) category, as it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, CAP, DIRS). It is a general operational update disseminated via the RNS system.
2023-12-20 English
POLB 001 Data Presented at ASH
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is dated 11 December 2023. It announces that Poolbeg Pharma PLC presented data at the 65th American Society of Hematology ('ASH') Annual Meeting. The content is a press release detailing scientific findings (POLB 001 for CRS) and includes contact information and boilerplate about the company and ASH. This format—a brief announcement of an event or data release, distributed via RNS—fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Since it is not a full report (like 10-K or IR) but a news item distributed through the regulatory news service, the most appropriate classification is Regulatory Filings (RNS), which serves as the general announcement fallback.
2023-12-11 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is an official announcement filed under RNS Number 1292V, dated November 30, 2023. The primary subject is explicitly stated as 'Directorate Change,' detailing the stepping down of an Independent Non-Executive Director and the subsequent appointments of new committee chairs. This content directly corresponds to the definition of 'Board/Management Information' (MANG). Although it is distributed via RNS, the specific nature of the content (director change) makes MANG the most accurate classification over the general RNS fallback.
2023-11-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.